Status:
COMPLETED
Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. Atherosclerosis is an...
Eligibility Criteria
Inclusion
- Cases:
- Subjects with non-small cell lung cancer treated with Immune Checkpoint Inhibitors.
- Available contrast enhanced CT scans of the chest both immediately pre-ICI (\< 1 month) and latest follow-up.
- Controls:
- Subjects with non-small cell lung cancer, age, cancer stage and cardiovascular risk factor matched to cases.
- Available contrast enhanced CT scan of the chest at two time-points at a similar interval between scans as the cases.
Exclusion
- none
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 22 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04430712
Start Date
August 1 2020
End Date
August 22 2022
Last Update
August 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114